A5080769448- Hemophilia Treatment and Research
- Platelet Disorders and Treatments
- Hemostasis and retained surgical items
- Chronic Myeloid Leukemia Treatments
City Clinical Hospital
2024
Г
Hemophilia A presents a serious problem, especially in its severe and inhibitor forms, leading to bleeding complications. The importance of studying the effectiveness safety new treatment approaches, particularly emicizumab, is undeniable for improving quality life patients. Aim: evaluate emicizumab prevention children with forms hemophilia A. Ethical approval was not required since study only involved use generalized retrospective data obtained during routine clinical practice. All were...
Hemophilia B – a deficiency of blood coagulation factor IX (FIX) is one the most common hereditary coagulopathies along with hemophilia A and von Willebrand disease. As in A, patients require prophylactic treatment to prevent development bleeding arthropathy, there number unsolved problems their treatment. At same time, arsenal drugs for significantly smaller compared therefore emergence new FIX great practical importance doctors patients. The article provides information about pathogenesis...
Surgeries in patients treated prophylactically with emicizumab (including surgical procedures a high risk of postoperative bleeding) are not associated higher risks or technical difficulties compared operations receiving standard replacement therapy. On the contrary, presence blood and its maintenance permanent basic hemostasis allow for reduction doses infusion time bypassing agents. Patients undergoing bleeding require an additional hemostatic treatment during first two three days after...
Surgeries in patients treated prophylactically with emicizumab (including surgical procedures a high risk of postoperative bleeding) are not associated higher risks or technical difficulties compared operations receiving standard replacement therapy. On the contrary, presence blood and its maintenance permanent basic hemostasis allow for reduction doses infusion time bypassing agents. Patients undergoing bleeding require an additional hemostatic treatment during first two three days after...